{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:46:05Z","timestamp":1792640765063,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"the Ministry of Health, Labor and Welfare of Japan","award":["n.a."],"award-info":[{"award-number":["n.a."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify predictive factors for scleroderma renal crisis (SRC) in patients with anti\u2013RNA polymerase III (anti\u2013RNAP III) antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 583 adult Japanese patients with systemic sclerosis (SSc) were screened for anti\u2013RNAP III using a commercially available enzyme\u2010linked immunosorbent assay (ELISA) kit. RNAP subsets were further identified by immunoprecipitation (IP) assays. The association of clinical and immunologic factors with SRC was examined by logistic analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this cohort, 37 patients (6%) were positive for anti\u2013RNAP III, as determined by anti\u2013RNAP III\u2013specific ELISA. Further IP assays revealed that 19 patients were positive for anti\u2013RNAP I\/III, 17 for anti\u2013RNAP I\/II\/III, and 1 for anti\u2010RNAP III. SRC occurred in a total of 17 (2.9%) of 583 patients, with a significantly higher frequency in anti\u2013RNAP III\u2013positive SSc patients (9 of 37 [24%]) than those without anti\u2013RNAP III (8 of 546 [1%]) (odds ratio [OR] 21.6 [95% confidence interval (95% CI) 7.8\u201360.3], <jats:italic>P<\/jats:italic> &lt; 0.00001). Our multivariate analyses using the Cox proportional hazards regression model revealed that anti\u2013RNAP I\/II\/III positivity (OR 11.0 [95% CI 1.6\u2013222.8], <jats:italic>P<\/jats:italic> = 0.0118) and an ELISA index for anti\u2013RNAP III of \u2265157 (OR 2.4 \u00d7 10<jats:sup>9<\/jats:sup> [95% CI 2.1\u2013uncalculated], <jats:italic>P<\/jats:italic> = 0.0093) were independent factors associated with the development of SRC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicate that anti\u2013RNAP III is associated with SRC, as reported previously. In addition, the presence of anti\u2013RNAP II in combination with anti\u2013RNAP I\/III (anti\u2013RNAP I\/II\/III) and a higher ELISA index for anti\u2013RNAP III may be associated with the development of SRC in SSc patients with anti\u2013RNAP III.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.38994","type":"journal-article","created":{"date-parts":[[2014,12,15]],"date-time":"2014-12-15T09:59:49Z","timestamp":1418637589000},"page":"1045-1052","source":"Crossref","is-referenced-by-count":78,"title":["Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti\u2013RNA Polymerase III Autoantibodies"],"prefix":"10.1002","volume":"67","author":[{"given":"Yasuhito","family":"Hamaguchi","sequence":"first","affiliation":[{"name":"Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Kodera","sequence":"additional","affiliation":[{"name":"Social Insurance Chukyo Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Inaba","sequence":"additional","affiliation":[{"name":"Social Insurance Chukyo Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Usuda","sequence":"additional","affiliation":[{"name":"Social Insurance Chukyo Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[{"name":"Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Kanazawa University, Kanazawa, Japan, and University of Tsukuba Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60641-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70297-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken307"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90986-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-8-200010170-00010"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.027"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27549"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_7_10_1","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy EC","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_11_1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis","volume":"15","author":"LeRoy EC","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_7_12_1","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements P","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22747"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370111"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24586"},{"key":"e_1_2_7_17_1","first-page":"12","article-title":"Anti\u2010PM\u2010Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik RW","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22163"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21232"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep290"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.52"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117550"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-798.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00007"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116343"},{"key":"e_1_2_7_26_1","first-page":"104","article-title":"Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis","volume":"34","author":"Meyer OC","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3544"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00016-4"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30111"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00964.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep215"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320911"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38994","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:57:18Z","timestamp":1759928238000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/art.38994"],"URL":"https:\/\/doi.org\/10.1002\/art.38994","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}